Therapeutic innovations against HIV
- 28 February 2006
- journal article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 16 (3) , 265-293
- https://doi.org/10.1517/13543776.16.3.265
Abstract
AIDS has become the leading cause of infection-associated mortality worldwide. Since the 1983 discovery of HIV as the aetiological agent of AIDS, numerous compounds have been developed to prevent or disrupt various stages of HIV replication. Three critical stages in the HIV life cycle have served as the molecular targets for 21 antiviral drugs in clinical use: i) the initial attachment of the virion to immune cells; ii) the transcription of viral RNA to viral DNA; and iii) the processing of gag-pol protein by HIV protease. This patent review discusses the therapeutic innovations against HIV-1, including both patented standard anti-HIV drugs in clinical use as well as promising new anti-HIV drug candidates in the pipeline.Keywords
This publication has 149 references indexed in Scilit:
- A peptide inhibitor of HIV-1 assembly in vitroNature Structural & Molecular Biology, 2005
- Capravirine, a Nonnucleoside Reverse‐Transcriptase Inhibitor in Patients Infected with HIV‐1: A Phase 1 StudyThe Journal of Infectious Diseases, 2004
- Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 InfectionNew England Journal of Medicine, 2004
- A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjectsAIDS, 2003
- The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replicationEuropean Journal of Immunology, 2002
- Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif proteinNature, 2002
- A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experienceAIDS, 1999
- Flexibility and function in HIV-1 proteaseNature Structural & Molecular Biology, 1995
- Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.Proceedings of the National Academy of Sciences, 1994
- Inhibition of reverse transcriptase of human immunodeficiency virus type 1 and chimeric enzymes of human immunodeficiency viruses types 1 and 2 by two novel non-nucleoside inhibitorsFEBS Letters, 1994